

Equities

10 August 2011 | 14 pages

Adani Enterprises (ADEL.BO)


Very Disappointing Quarter

- Recurring PAT at Rs5.7bn is 28% below expectations The variance v/s CIRA of Rs2.4bn at PBT level was explained by 1) Rs1.4bn lower trading EBITDA; 2) Rs600mn of higher net interest (interest + other income); 3) lower EBITDA from others.
- Coal trading margins crumble Volumes of 10.2mn tons were up 23% YoY (CIRA 11mn tons) and ASP was US\$114/ton assuming USDINR 45 (v/s CIRA US\$100/ton). EBITDA/ton was disappointing at US\$7.8/ton (v/s CIRA US\$10/ton management guidance). ADE took ~Rs460mn provision in trading on receivables > 365 days. If we add back the same EBITDA/ton at US\$8.8/ton is still disappointing v/s expectations.
- Adani Power PAT 26% below expectations Lower merchant sales in 1Q12 suggest a big quantum from unit # 1 660MW was sold at PPA rates even before start of PPA. This raises questions on business model of making supernormal RoEs by selling power at merchant rates (Rs3.50-4.50/kWh) v/s PPA rates (Rs2.35-2.90/kWh) pre PPA.
- MPSEZ PAT 12% below expectations PAT at Rs2.54bn +20% YoY was 12% below CIRA at Rs2.89bn. Sales at Rs5.1bn was up 27% YoY and EBITDA Margins at 67.8% declined 124bps YoY, but was better than expected. There was disappointment on liquid cargo volumes (expected to spill over to subsequent quarters). Dry bulk and containers (+24%) remain robust. Coal volumes were better than expected.
- Maintain Hold (2M) Revising down target price to Rs644 (from Rs653 earlier) to factor in (1) 6-20% EPS cut over FY12E-15E (2) roll forward of all multiples and DCF values by 3 months (3) Adani Power at our new target price of Rs105 and (3) removing the 5% conglomerate discount. We revise down our EPS estimates by 6-20% over FY12E-15E to factor in (1) our recent 3-40% EPS cut in Adani Power and (2) Lower coal trading EBITDA/ton of US\$8.5/ton in FY12E and US\$8.8/ton over FY13E-15E.

- Company Update
- Target Price Change
- Estimate Change

Hold/Medium Risk	2M
Price (10 Aug 11)	Rs585.00
Target price	Rs644.00
from Rs653.00	
Expected share price return	10.1%
Expected dividend yield	0.2%
Expected total return	10.3%
Market Cap	Rs643,389M
	US\$14,231M

Price Performance
(RIC: ADEL.BO, BB: ADE IN)



Year to	Net Profit	Diluted EPS	EPS growth	P/E	P/B	ROE	Yield
31 Mar	(RsM)	(Rs)	(%)	(x)	(x)	(%)	(%)
2010A	9,158	18.39	79.0	31.8	4.8	20.3	0.2
2011A	24,409	22.19	20.7	26.4	3.7	20.8	0.2
2012E	34,253	31.14	40.3	18.8	3.1	18.0	0.2
2013E	51,768	47.07	51.1	12.4	2.5	22.4	0.4
2014E	66,806	60.74	29.0	9.6	2.0	23.2	0.5

Venkatesh Balasubramaniam

+91-22-6631-9864

venkatesh.balasubramaniam@citi.com

Deepal Delivala

+91-22-6631-9857 deepal.delivala@citi.com

Atul Tiwari, CFA atul.tiwari@citi.com

Rishi V Iyer rishi.iyer@citi.com

See Appendix A-1 for Analyst Certification, Important Disclosures and non-US research analyst disclosures.

Citi Investment Research & Analysis is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

Fiscal year end 31-Mar

P/E adjusted (x) 31.8 26.4 18.8 12.4 9.6 EV/EBITDA adjusted (x) 45.7 22.2 14.9 9.6 7.2 P/BV (x) 4.8 3.7 3.1 2.5 2.0 Dividend yield (%) 0.2 0.2 0.2 0.4 0.5 Per Share Data (Rs) EPS adjusted 18.39 22.19 31.14 47.07 60.74 EPS reported 18.46 22.51 31.14 47.07 60.74 BVPS 120.97 158.58 188.09 232.68 290.22 DPS 1.00 1.00 1.38 2.09 2.70 Profit & Loss (RsM) Net sales 258,899 263,180 379,545 529,449 637,523 Operating expenses -243,523 -228,673 -319,581 -428,984 -505,169 EBIT 15,376 34,507 59,964 100,465 132,354 Net interest expense -5,079 -5,131 -13,904 -28,014 <th>riscai yeai enu 31-iviai</th> <th>2010</th> <th>2011</th> <th>2012</th> <th>2013</th> <th>2014E</th>	riscai yeai enu 31-iviai	2010	2011	2012	2013	2014E
EVIEBÍTDA adjusted (x)	Valuation Ratios					
PIBV (x)	P/E adjusted (x)	31.8	26.4	18.8	12.4	9.6
PIBV (x)		45.7	22.2	14.9	9.6	7.2
Per Share Data (Rs) EPS adjusted 18.39 22.19 31.14 47.07 60.74 EPS reported 18.46 22.51 31.14 47.07 60.74 BVPS 120.97 158.58 188.09 232.68 290.22 DPS 1.00 1.00 1.38 209 2.70 Profit & Loss (RsM) Non-toperating expenses -243.523 -228.673 -319.581 -428,984 -505,169 EBIT 15,376 34,507 59.964 100,465 123,354 Pre tax profit 10,632 32,382 47,955 74,328 97,948 Tax -937 4,475 5,971 -9,416 -13,113 Extraord / Min. Int./Pref.div. -502 3,146 -7,730 -13,143 -18,042 Reported net income 9,193 24,761 34,253 51,768 66,806 Adjusted EBITDA 16,890 40,093 70,142 116,509 154,794 Growth Rates (%) 58les -1,4 1,7	P/BV (x)	4.8	3.7	3.1	2.5	2.0
EPS adjusted 18.39 22.19 31.14 47.07 60.74 EPS reported 18.46 22.51 31.14 47.07 60.74 EPS reported 19.40 1.00 1.00 1.38 2.09 2.70 Profit & Loss (RSM) Net sales 256.899 263.180 379.545 529.449 637.523 Operating expenses 243.523 -228.673 -319.881 428.984 505.169 EBIT 15,376 34.507 59,964 100,465 132.354 Net interest expense -5.079 5.131 -13.904 28.014 -36.251 Non-operating/exceptionals 335 3.006 1.895 18.77 1.845 Pre-tax profit 10,632 32.382 47.955 74,328 97,948 Tax -937 4.475 5.971 -9,416 -13.113 Extraord/Min.Int./Pref.div502 -3.146 -7.730 -13.143 -18.029 Reported net income 9,193 24,761 34,253 51,768 66,806 Adjusted earnings 9,158 24,409 34,253 51,768 66,806 Adjusted EBITDA 16,890 40,093 70,142 116,509 154,794 Growth Rates (%) Sales -1.4 1.7 44.2 39.5 20.4 EBIT adjusted 67.2 124.4 73.8 67.5 31.7 EBIT adjusted 68.6 137.4 75.0 66.1 32.9 EBIT adjusted 68.6 137.4 75.0 66.1 32.9 EBIT DA adjusted 68.6 137.4 75.0 66.1 32.9 EPS adjusted 79.0 20.7 40.3 51.1 29.0 Cash Flow (RSM) Operating cash flow 93,986 -282,353 -77,778 74,988 49,109 Capital expenditure 91,949 -288,709 -79,436 -76,627 -33,239 Net working capital -2,415 -20,660 -87,233 -18,194 -10,347 Investing cash flow 93,986 -282,353 -77,778 -74,988 49,109 Capital expenditure 91,949 -282,709 -79,436 -76,627 -33,239 Net working cash flow 93,986 -282,353 -77,778 -74,988 -49,109 Capital expenditure 91,949 -288,709 -79,436 -76,627 -33,239 Net working cash flow 93,986 -282,353 -77,778 -74,988 -49,109 Capital expenditure 91,949 -286,709 -79,436 -76,627 -33,239 Net working cash flow 93,986 -282,353 -77,778 -74,988 -49,109 Capital expenditure 91,949 -286,709 -79,436 -76,627 -33,239 Net working cash flow 93,986 -282,353 -77,778 -74,988 -49,109 Capital expenditure 91,949 -286,709 -79,436 -76,627 -35,218 Dorrowings 53,546 53,240 -66,709 -79,436 -76,627 -35,218 Dorrowings 53,546 53,240 -66,709 -79,436 -7	Dividend yield (%)	0.2	0.2	0.2	0.4	0.5
EPS reported 18.46 22.51 31.14 47.07 60.74 BVPS 120.97 158.58 188.09 22.68 290.22 DPS 1.00 1.00 1.38 2.09 2.70 Profit & Loss (RSM) V V V V 429.944 637,523 Operating expenses -243,523 -228,673 -319,881 426,984 -505,169 BBIT 15,376 34,507 59,664 100,465 132,354 Not interest expense -5,079 -5,131 -13,904 -28,014 -36,251 Non-operating/exceptionals 335 3,006 1,895 1,877 1,845 Pre-tax profit 10,632 32,382 47,955 74,328 97,948 Tax -937 -4,475 -5,971 -9,416 -13,113 -18,029 Reported net income 9,193 24,761 34,253 51,768 66,806 Adjusted EBITDA 16,890 40,093 70,142 116,509 154,	Per Share Data (Rs)					
BVPS	EPS adjusted	18.39	22.19	31.14	47.07	60.74
DPS	EPS reported	18.46	22.51	31.14	47.07	60.74
Profit & Loss (RsM)	BVPS	120.97	158.58	188.09	232.68	290.22
Net sales	DPS	1.00	1.00	1.38	2.09	2.70
Operating expenses -243,523 -228,673 -319,581 -428,984 -505,169 EBIT 15,376 34,507 59,964 100,465 132,354 Non-operating/exceptionals 335 3,006 1,895 1,877 1,845 Pre-tax profit 10,632 32,382 47,955 74,328 97,948 Tax 937 4,475 -5,971 9,416 -13,113 Extraord/Min.Intr/Pref.div. -502 -3,146 -7,730 -13,143 -18,029 Reported net income 9,193 24,761 34,253 51,768 66,806 Adjusted earnings 9,158 24,409 34,253 51,768 66,806 Adjusted EBITDA 16,890 40,093 70,142 116,509 154,794 EBIT adjusted 67.2 124.4 73.8 67.5 31.7 EBITDA adjusted 68.6 137,4 75.0 66.1 32.9 Cash Flow (RsM) O 20.7 40.3 51.1 29.0	Profit & Loss (RsM)					
EBIT 15,376 34,507 59,964 100,465 132,354 Net interest expense -5,079 -5,131 -13,904 -28,014 -36,251 Non-operating/exceptionals 335 3,006 1,895 1,877 1,845 Pre-tax profit 10,632 32,382 47,955 74,328 97,948 Tax -937 -4,475 -5,971 -9,416 -13,113 -18,029 Reported net income 9,193 24,761 34,253 51,768 66,806 Adjusted earnings 9,158 24,409 34,253 51,768 66,806 Adjusted EBITDA 16,890 40,093 70,142 116,509 154,794 Growth Rates (%) Sales -1.4 1.7 44.2 39.5 20.4 EBIT adjusted 67.2 124.4 73.8 67.5 31.7 EBIT adjusted 68.6 137.4 75.0 66.1 32.9 Cash Flow (RsM) 10 20.7 40.3 51.1 2	Net sales	258,899	263,180	379,545	529,449	637,523
BBIT	Operating expenses			-319,581	-428,984	-505,169
Net interest expense	EBIT	15,376	34,507	59,964	100,465	132,354
Non-operating/exceptionals 335 3,006 1,895 1,877 1,845 Pre-tax profit 10,632 32,382 47,955 74,328 97,948 Tax	Net interest expense					-36,251
Pre-tax profit 10,632 32,382 47,955 74,328 97,948 Tax -937 -4,475 -5,971 -9,416 -13,113			3,006	1,895	1,877	1,845
Tax	Pre-tax profit					97,948
Extraord/Min.Int/Pref.div502 -3,146 -7,730 -13,143 -18,029 Reported net income 9,193 24,761 34,253 51,768 66,806 Adjusted earnings 9,158 24,409 34,253 51,768 66,806 Adjusted EBITDA 16,890 40,093 70,142 116,509 154,794 Growth Rates (%) Sales -1.4 1.7 44.2 39.5 20.4 EBIT adjusted 67.2 124.4 73.8 67.5 31.7 EBITDA adjusted 68.6 137.4 75.0 66.1 32.9 EPS adjusted 79.0 20.7 40.3 51.1 29.0 Cash Flow (RsM) Operating cash flow 14,114 24,248 -25,417 86,087 127,227 Depreciation/amortization 1,515 5,586 10,178 16,044 22,439 Net working capital -2,415 -20,660 -87,233 -18,194 -10,347 Investing cash flow -91,949 -288,709 -79,436 -76,627 -33,239 Acquisitions/disposals 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Tax					-13,113
Reported net income 9,193 24,761 34,253 51,768 66,806 Adjusted earnings 9,158 24,409 34,253 51,768 66,806 Adjusted EBITDA 16,890 40,093 70,142 116,509 154,794 Growth Rates (%) Sales -1.4 1.7 44.2 39.5 20.4 EBIT adjusted 67.2 124.4 73.8 67.5 31.7 EBITDA adjusted 68.6 137.4 75.0 66.1 32.9 EPS adjusted 79.0 20.7 40.3 51.1 29.0 Cash Flow (RsM) Cash Flow (RsM) 0 0.7 40.3 51.1 29.0 Depreciating cash flow 14,114 24,248 -25,417 86,087 127,227 Depreciation/amortization 1,515 5,586 10,178 16,044 22,439 Net working capital -2,415 -20,660 -87,233 -18,194 -10,347 Investing cash flow -93,986 -282,353 -77,778	Extraord./Min.Int./Pref.div.					-18,029
Adjusted earnings 9,158 24,409 34,253 51,768 66,806 Adjusted EBITDA 16,890 40,093 70,142 116,509 154,794 Growth Rates (%) Sales -1.4 1.7 44.2 39.5 20.4 EBIT adjusted 67.2 124.4 73.8 67.5 31.7 EBIT DA adjusted 68.6 137.4 75.0 66.1 32.9 EPS adjusted 79.0 20.7 40.3 51.1 29.0 Cash Flow (RsM) Operating cash flow 14,114 24,248 -25,417 86,087 127,227 Depreciation/amortization 1,515 5,586 10,178 16,044 22,439 Net working capital -2,415 -20,660 87,233 -18,194 -10,347 Investing cash flow -93,986 -282,353 -77,778 -74,988 49,109 Capital expenditure -91,949 -288,709 -79,436 -76,627 -33,239 Acquisitions/disposals 0 0 0 0 0 0 0 0 Financing cash flow 83,228 257,420 152,814 -17,549 -22,138 Borrowings 53,546 153,240 166,791 9,642 12,777 Dividends paid -581 -1,304 -1,804 -2,726 -3,518 Change in cash 3,356 -685 49,619 -6,450 55,979 Balance Sheet (RsM) Total assets 304,027 635,968 817,112 900,848 1,003,280 Cash & cash equivalent 29,188 28,503 78,122 71,672 127,651 Accounts receivable 30,264 65,335 52,686 68,013 76,448 Net fixed assets 179,139 462,262 531,521 592,104 602,903 Total liabilities 225,264 426,465 567,430 588,981 610,095 Accounts payable 29,490 49,966 34,289 41,453 46,374 Total Debt 174,389 327,629 494,419 504,061 516,839 Shareholders' funds 78,763 209,503 249,682 311,868 393,185 Profitability/Solvency Ratios (%) EBITDA margin adjusted 8.3 8.1 9.0 12.6 15.5 Net debt to equity 184.4 142.8 166.7 138.6 99.0	Reported net income	9,193				66,806
Adjusted EBITDA 16,890 40,093 70,142 116,509 154,794 Growth Rates (%) Sales -1.4 1.7 44.2 39.5 20.4 EBIT adjusted 67.2 124.4 73.8 67.5 31.7 EBITDA adjusted 68.6 137.4 75.0 66.1 32.9 Cash Flow (RsM) Cash Flow (RsM) Operating cash flow 14,114 24,248 -25,417 86,087 127,227 Depreciation/amortization 1,515 5,586 10,178 16,044 22,439 Net working capital -2,415 -20,660 -87,233 -18,194 -10,347 Investing cash flow -93,986 -282,353 -77,778 -74,988 -49,109 Capital expenditure -91,949 -288,709 -79,436 -76,627 -33,239 Acquisitions/disposals 0 0 0 0 0 0 0 Financing cash flow 83,228 257,420 152,814 -17,549 -22,138	-				51,768	66,806
Growth Rates (%) Sales -1.4 1.7 44.2 39.5 20.4 EBIT adjusted 67.2 124.4 73.8 67.5 31.7 EBITDA adjusted 68.6 137.4 75.0 66.1 32.9 EPS adjusted 79.0 20.7 40.3 51.1 29.0 Cash Flow (RsM) Operating cash flow (RsM) Operating cash flow 14,114 24,248 -25,417 86,087 127,227 Depreciation/amortization 1,515 5,586 10,178 16,044 22,439 Net working capital -2,415 -20,660 -87,233 -18,194 -10,347 Investing cash flow -93,986 -282,353 -77,778 -74,988 -49,109 Capital expenditure -91,949 -288,709 -79,436 -76,627 -33,239 Acquisitions/disposals 0 0 0 0 0 0 Borrowings 53,546 153,240 166,791 9,642 12,776 Chang	-					154,794
Sales -1.4 1.7 44.2 39.5 20.4 EBIT adjusted 67.2 124.4 73.8 67.5 31.7 EBITDA adjusted 68.6 137.4 75.0 66.1 32.9 EPS adjusted 79.0 20.7 40.3 51.1 29.0 Cash Flow (RsM) Operating cash flow (RsM) 14,114 24,248 -25,417 86,087 127,227 Depreciation/amortization 1,515 5,586 10,178 16,044 22,439 Net working capital -2,415 -20,660 -87,233 -18,194 -10,347 Investing cash flow -93,986 -282,353 -77,778 -74,988 -49,109 Capital expenditure -91,949 -288,709 -79,436 -76,627 -33,239 Acquisitions/disposals 0 0 0 0 0 0 0 Financing cash flow 83,228 257,420 152,814 -17,549 -22,138 Borrowings 53,546	-	•				
EBITDA adjusted 68.6 137.4 75.0 66.1 32.9 EPS adjusted 79.0 20.7 40.3 51.1 29.0 Cash Flow (RsM) Operating cash flow 14,114 24,248 -25,417 86,087 127,227 Depreciation/amortization 1,515 5,586 10,178 16,044 22,439 Net working capital -2,415 -20,660 -87,233 -18,194 -10,347 Investing cash flow -93,986 -282,353 -77,778 -74,988 -49,109 Capital expenditure -91,949 -288,709 -79,436 -76,627 -33,239 Acquisitions/disposals 0 0 0 0 0 0 0 0 0 0 Financing cash flow 83,228 257,420 152,814 -17,549 -22,138 Borrowings 53,546 153,240 166,791 9,642 12,777 Dividends paid -581 -1,304 -1,804 -2,726 -3,518 Change in cash 3,356 -685 49,619 -6,450 55,979 Balance Sheet (RsM) Total assets 304,027 635,968 817,112 900,848 1,003,280 Cash & cash equivalent 29,188 28,503 78,122 71,672 127,651 Accounts receivable 30,264 65,335 52,686 68,013 76,484 Accounts receivable 30,264 426,465 567,430 588,981 610,095 Accounts payable 29,490 49,966 34,289 41,453 46,374 Total liabilities 225,264 426,465 567,430 588,981 610,095 Accounts payable 29,490 49,966 34,289 41,453 46,374 Total Debt 174,389 327,629 494,419 504,061 516,839 Shareholders' funds 78,763 209,503 249,682 311,868 393,185 Profitability/Solvency Ratios (%) EBITDA margin adjusted 6.5 15.2 18.5 22.0 24.3 ROIC adjusted 8.3 8.1 9.0 12.6 15.5 Net debt to equity 184.4 142.8 166.7 138.6 99.0	Sales	-1.4	1.7	44.2	39.5	20.4
EBITDA adjusted 68.6 137.4 75.0 66.1 32.9 EPS adjusted 79.0 20.7 40.3 51.1 29.0 Cash Flow (RsM) Operating cash flow 14,114 24,248 -25,417 86,087 127,227 Depreciation/amortization 1,515 5,586 10,178 16,044 22,439 Net working capital -2,415 -20,660 -87,233 -18,194 -10,347 Investing cash flow -93,986 -282,353 -77,778 -74,988 -49,109 Capital expenditure -91,949 -288,709 -79,436 -76,627 -33,239 Acquisitions/disposals 0 0 0 0 0 0 0 0 0 0 0 5 inancing cash flow 83,228 257,420 152,814 -17,549 -22,138 Borrowings 53,546 153,240 166,791 9,642 12,777 Dividends paid -581 -1,304 -1,804 -2,726 -3,518 Change in cash 3,356 -685 49,619 -6,450 55,979 Balance Sheet (RsM) Total assets 304,027 635,968 817,112 900,848 1,003,280 Cash & cash equivalent 29,188 28,503 78,122 71,672 127,651 Accounts receivable 30,264 65,335 52,686 68,013 76,484 Accounts receivable 30,264 426,465 567,430 588,981 610,095 Accounts payable 29,490 49,966 34,289 41,453 46,374 Total liabilities 225,264 426,465 567,430 588,981 610,095 Accounts payable 29,490 49,966 34,289 41,453 46,374 Total Debt 174,389 327,629 494,419 504,061 516,839 Shareholders' funds 78,763 209,503 249,682 311,868 393,185 Profitability/Solvency Ratios (%) EBITDA margin adjusted 6.5 15.2 18.5 22.0 24.3 ROIC adjusted 8.3 8.1 9.0 12.6 15.5 Net debt to equity 184.4 142.8 166.7 138.6 99.0	EBIT adjusted	67.2	124.4	73.8		31.7
EPS adjusted 79.0 20.7 40.3 51.1 29.0 Cash Flow (RsM) Operating cash flow 14,114 24,248 -25,417 86,087 127,227 Depreciation/amortization 1,515 5,586 10,178 16,044 22,439 Net working capital -2,415 -20,660 -87,233 -18,194 -10,347 Investing cash flow -93,986 -282,353 -77,778 -74,988 -49,109 Capital expenditure -91,949 -288,709 -79,436 -76,627 -33,239 Acquisitions/disposals 0	-	68.6			66.1	32.9
Operating cash flow 14,114 24,248 -25,417 86,087 127,227 Depreciation/amortization 1,515 5,586 10,178 16,044 22,439 Net working capital -2,415 -20,660 -87,233 -18,194 -10,347 Investing cash flow -93,986 -282,353 -77,778 -74,988 -49,109 Capital expenditure -91,949 -288,709 -79,436 -76,627 -33,239 Acquisitions/disposals 0 0 0 0 0 0 Financing cash flow 83,228 257,420 152,814 -17,549 -22,138 Borrowings 53,546 153,240 166,791 9,642 12,777 Dividends paid -581 -1,304 -1,804 -2,726 -3,518 Change in cash 3,356 -685 49,619 -6,450 55,979 Balance Sheet (RsM) 20,188 28,503 78,122 71,672 127,651 Accounts receivable 30,264 65,335 5	EPS adjusted	79.0	20.7	40.3	51.1	29.0
Depreciation/amortization 1,515 5,586 10,178 16,044 22,439 Net working capital -2,415 -20,660 -87,233 -18,194 -10,347 Investing cash flow -93,986 -282,353 -77,778 -74,988 -49,109 Capital expenditure -91,949 -288,709 -79,436 -76,627 -33,239 Acquisitions/disposals 0 0 0 0 0 0 Financing cash flow 83,228 257,420 152,814 -17,549 -22,138 Borrowings 53,546 153,240 166,791 9,642 12,777 Dividends paid -581 -1,304 -1,804 -2,726 -3,518 Change in cash 3,356 -685 49,619 -6,450 55,979 Balance Sheet (RsM) Total assets 304,027 635,968 817,112 900,848 1,003,280 Cash & cash equivalent 29,188 28,503 78,122 71,672 127,651 Accounts receivable 30,264	Cash Flow (RsM)					
Depreciation/amortization 1,515 5,586 10,178 16,044 22,439 Net working capital -2,415 -20,660 -87,233 -18,194 -10,347 Investing cash flow -93,986 -282,353 -77,778 -74,988 -49,109 Capital expenditure -91,949 -288,709 -79,436 -76,627 -33,239 Acquisitions/disposals 0 0 0 0 0 0 Financing cash flow 83,228 257,420 152,814 -17,549 -22,138 Borrowings 53,546 153,240 166,791 9,642 12,777 Dividends paid -581 -1,304 -1,804 -2,726 -3,518 Change in cash 3,356 -685 49,619 -6,450 55,979 Balance Sheet (RsM) Total assets 304,027 635,968 817,112 900,848 1,003,280 Cash & cash equivalent 29,188 28,503 78,122 71,672 127,651 Accounts receivable 30,264	Operating cash flow	14,114	24,248	-25,417	86,087	127,227
Net working capital -2,415 -20,660 -87,233 -18,194 -10,347 Investing cash flow -93,986 -282,353 -77,778 -74,988 -49,109 Capital expenditure -91,949 -288,709 -79,436 -76,627 -33,239 Acquisitions/disposals 0 0 0 0 0 0 Financing cash flow 83,228 257,420 152,814 -17,549 -22,138 Borrowings 53,546 153,240 166,791 9,642 12,777 Dividends paid -581 -1,304 -1,804 -2,726 -3,518 Change in cash 3,356 -685 49,619 -6,450 55,979 Balance Sheet (RsM) Total assets 304,027 635,968 817,112 900,848 1,003,280 Cash & cash equivalent 29,188 28,503 78,122 71,672 127,651 Accounts receivable 30,264 65,335 52,686 68,013 76,484 Net fixed assets 179,139	. •					22,439
Investing cash flow -93,986 -282,353 -77,778 -74,988 -49,109 Capital expenditure -91,949 -288,709 -79,436 -76,627 -33,239 Acquisitions/disposals 0 0 0 0 0 0 Financing cash flow 83,228 257,420 152,814 -17,549 -22,138 Borrowings 53,546 153,240 166,791 9,642 12,777 Dividends paid -581 -1,304 -1,804 -2,726 -3,518 Change in cash 3,356 -685 49,619 -6,450 55,979 Balance Sheet (RsM) 70 635,968 817,112 900,848 1,003,280 Cash & cash equivalent 29,188 28,503 78,122 71,672 127,651 Accounts receivable 30,264 65,335 52,686 68,013 76,484 Net fixed assets 179,139 462,262 531,521 592,104 602,903 Total liabilities 225,264 426,465 567,						-10,347
Capital expenditure -91,949 -288,709 -79,436 -76,627 -33,239 Acquisitions/disposals 0 0 0 0 0 0 Financing cash flow 83,228 257,420 152,814 -17,549 -22,138 Borrowings 53,546 153,240 166,791 9,642 12,777 Dividends paid -581 -1,304 -1,804 -2,726 -3,518 Change in cash 3,356 -685 49,619 -6,450 55,979 Balance Sheet (RsM) 50,460 817,112 900,848 1,003,280 Cash & cash equivalent 29,188 28,503 78,122 71,672 127,651 Accounts receivable 30,264 65,335 52,686 68,013 76,484 Net fixed assets 179,139 462,262 531,521 592,104 602,903 Total liabilities 225,264 426,465 567,430 588,981 610,095 Accounts payable 29,490 49,966 34,289 41,453<						-49,109
Acquisitions/disposals 0 0 0 0 0 Financing cash flow 83,228 257,420 152,814 -17,549 -22,138 Borrowings 53,546 153,240 166,791 9,642 12,777 Dividends paid -581 -1,304 -1,804 -2,726 -3,518 Change in cash 3,356 -685 49,619 -6,450 55,979 Balance Sheet (RsM) 53,356 -685 49,619 -6,450 55,979 Cash & cash equivalent 29,188 28,503 78,122 71,672 127,651 Accounts receivable 30,264 65,335 52,686 68,013 76,484 Net fixed assets 179,139 462,262 531,521 592,104 602,903 Total liabilities 225,264 426,465 567,430 588,981 610,095 Accounts payable 29,490 49,966 34,289 41,453 46,374 Total Debt 174,389 327,629 494,419 504,061						-33,239
Borrowings 53,546 153,240 166,791 9,642 12,777 Dividends paid -581 -1,304 -1,804 -2,726 -3,518 Change in cash 3,356 -685 49,619 -6,450 55,979 Balance Sheet (RsM) Total assets 304,027 635,968 817,112 900,848 1,003,280 Cash & cash equivalent 29,188 28,503 78,122 71,672 127,651 Accounts receivable 30,264 65,335 52,686 68,013 76,484 Net fixed assets 179,139 462,262 531,521 592,104 602,903 Total liabilities 225,264 426,465 567,430 588,981 610,095 Accounts payable 29,490 49,966 34,289 41,453 46,374 Total Debt 174,389 327,629 494,419 504,061 516,839 Shareholders' funds 78,763 209,503 249,682 311,868 393,185 Profitability/Solvency Ratios 6.5	Acquisitions/disposals	0	0	0	0	0
Borrowings 53,546 153,240 166,791 9,642 12,777 Dividends paid -581 -1,304 -1,804 -2,726 -3,518 Change in cash 3,356 -685 49,619 -6,450 55,979 Balance Sheet (RsM) Total assets 304,027 635,968 817,112 900,848 1,003,280 Cash & cash equivalent 29,188 28,503 78,122 71,672 127,651 Accounts receivable 30,264 65,335 52,686 68,013 76,484 Net fixed assets 179,139 462,262 531,521 592,104 602,903 Total liabilities 225,264 426,465 567,430 588,981 610,095 Accounts payable 29,490 49,966 34,289 41,453 46,374 Total Debt 174,389 327,629 494,419 504,061 516,839 Shareholders' funds 78,763 209,503 249,682 311,868 393,185 Profitability/Solvency Ratios 6.5	Financing cash flow	83,228	257,420	152,814	-17,549	-22,138
Dividends paid -581 -1,304 -1,804 -2,726 -3,518 Change in cash 3,356 -685 49,619 -6,450 55,979 Balance Sheet (RsM) Total assets 304,027 635,968 817,112 900,848 1,003,280 Cash & cash equivalent 29,188 28,503 78,122 71,672 127,651 Accounts receivable 30,264 65,335 52,686 68,013 76,484 Net fixed assets 179,139 462,262 531,521 592,104 602,903 Total liabilities 225,264 426,465 567,430 588,981 610,095 Accounts payable 29,490 49,966 34,289 41,453 46,374 Total Debt 174,389 327,629 494,419 504,061 516,839 Shareholders' funds 78,763 209,503 249,682 311,868 393,185 Profitability/Solvency Ratios (%) EBITDA margin adjusted 6.5 15.2 18.5 22.0 24.3						12,777
Change in cash 3,356 -685 49,619 -6,450 55,979 Balance Sheet (RsM) Total assets 304,027 635,968 817,112 900,848 1,003,280 Cash & cash equivalent 29,188 28,503 78,122 71,672 127,651 Accounts receivable 30,264 65,335 52,686 68,013 76,484 Net fixed assets 179,139 462,262 531,521 592,104 602,903 Total liabilities 225,264 426,465 567,430 588,981 610,095 Accounts payable 29,490 49,966 34,289 41,453 46,374 Total Debt 174,389 327,629 494,419 504,061 516,839 Shareholders' funds 78,763 209,503 249,682 311,868 393,185 Profitability/Solvency Ratios (%) EBITDA margin adjusted 6.5 15.2 18.5 22.0 24.3 ROE adjusted 20.3 20.8 18.0 22.4 23.2	Dividends paid		-1,304		-2,726	-3,518
Balance Sheet (RsM) Total assets 304,027 635,968 817,112 900,848 1,003,280 Cash & cash equivalent 29,188 28,503 78,122 71,672 127,651 Accounts receivable 30,264 65,335 52,686 68,013 76,484 Net fixed assets 179,139 462,262 531,521 592,104 602,903 Total liabilities 225,264 426,465 567,430 588,981 610,095 Accounts payable 29,490 49,966 34,289 41,453 46,374 Total Debt 174,389 327,629 494,419 504,061 516,839 Shareholders' funds 78,763 209,503 249,682 311,868 393,185 Profitability/Solvency Ratios (%) EBITDA margin adjusted 6.5 15.2 18.5 22.0 24.3 ROE adjusted 8.3 8.1 9.0 12.6 15.5 Net debt to equity 184.4 142.8 166.7 138.6 99.0	Change in cash	3,356	-685	49,619	-6,450	55,979
Cash & cash equivalent 29,188 28,503 78,122 71,672 127,651 Accounts receivable 30,264 65,335 52,686 68,013 76,484 Net fixed assets 179,139 462,262 531,521 592,104 602,903 Total liabilities 225,264 426,465 567,430 588,981 610,095 Accounts payable 29,490 49,966 34,289 41,453 46,374 Total Debt 174,389 327,629 494,419 504,061 516,839 Shareholders' funds 78,763 209,503 249,682 311,868 393,185 Profitability/Solvency Ratios (%) EBITDA margin adjusted 6.5 15.2 18.5 22.0 24.3 ROE adjusted 20.3 20.8 18.0 22.4 23.2 ROIC adjusted 8.3 8.1 9.0 12.6 15.5 Net debt to equity 184.4 142.8 166.7 138.6 99.0	Balance Sheet (RsM)					
Cash & cash equivalent 29,188 28,503 78,122 71,672 127,651 Accounts receivable 30,264 65,335 52,686 68,013 76,484 Net fixed assets 179,139 462,262 531,521 592,104 602,903 Total liabilities 225,264 426,465 567,430 588,981 610,095 Accounts payable 29,490 49,966 34,289 41,453 46,374 Total Debt 174,389 327,629 494,419 504,061 516,839 Shareholders' funds 78,763 209,503 249,682 311,868 393,185 Profitability/Solvency Ratios (%) EBITDA margin adjusted 6.5 15.2 18.5 22.0 24.3 ROE adjusted 20.3 20.8 18.0 22.4 23.2 ROIC adjusted 8.3 8.1 9.0 12.6 15.5 Net debt to equity 184.4 142.8 166.7 138.6 99.0	Total assets	304,027	635,968	817,112	900,848	1,003,280
Accounts receivable 30,264 65,335 52,686 68,013 76,484 Net fixed assets 179,139 462,262 531,521 592,104 602,903 Total liabilities 225,264 426,465 567,430 588,981 610,095 Accounts payable 29,490 49,966 34,289 41,453 46,374 Total Debt 174,389 327,629 494,419 504,061 516,839 Shareholders' funds 78,763 209,503 249,682 311,868 393,185 Profitability/Solvency Ratios (%) EBITDA margin adjusted 6.5 15.2 18.5 22.0 24.3 ROE adjusted 20.3 20.8 18.0 22.4 23.2 ROIC adjusted 8.3 8.1 9.0 12.6 15.5 Net debt to equity 184.4 142.8 166.7 138.6 99.0						
Net fixed assets 179,139 462,262 531,521 592,104 602,903 Total liabilities 225,264 426,465 567,430 588,981 610,095 Accounts payable 29,490 49,966 34,289 41,453 46,374 Total Debt 174,389 327,629 494,419 504,061 516,839 Shareholders' funds 78,763 209,503 249,682 311,868 393,185 Profitability/Solvency Ratios (%) EBITDA margin adjusted 6.5 15.2 18.5 22.0 24.3 ROE adjusted 20.3 20.8 18.0 22.4 23.2 ROIC adjusted 8.3 8.1 9.0 12.6 15.5 Net debt to equity 184.4 142.8 166.7 138.6 99.0	•					
Total liabilities 225,264 426,465 567,430 588,981 610,095 Accounts payable 29,490 49,966 34,289 41,453 46,374 Total Debt 174,389 327,629 494,419 504,061 516,839 Shareholders' funds 78,763 209,503 249,682 311,868 393,185 Profitability/Solvency Ratios (%) EBITDA margin adjusted 6.5 15.2 18.5 22.0 24.3 ROE adjusted 20.3 20.8 18.0 22.4 23.2 ROIC adjusted 8.3 8.1 9.0 12.6 15.5 Net debt to equity 184.4 142.8 166.7 138.6 99.0		•	•			
Accounts payable 29,490 49,966 34,289 41,453 46,374 Total Debt 174,389 327,629 494,419 504,061 516,839 Shareholders' funds 78,763 209,503 249,682 311,868 393,185 Profitability/Solvency Ratios (%) EBITDA margin adjusted 6.5 15.2 18.5 22.0 24.3 ROE adjusted 20.3 20.8 18.0 22.4 23.2 ROIC adjusted 8.3 8.1 9.0 12.6 15.5 Net debt to equity 184.4 142.8 166.7 138.6 99.0				•		
Total Debt 174,389 327,629 494,419 504,061 516,839 Shareholders' funds 78,763 209,503 249,682 311,868 393,185 Profitability/Solvency Ratios (%) EBITDA margin adjusted 6.5 15.2 18.5 22.0 24.3 ROE adjusted 20.3 20.8 18.0 22.4 23.2 ROIC adjusted 8.3 8.1 9.0 12.6 15.5 Net debt to equity 184.4 142.8 166.7 138.6 99.0						
Shareholders' funds 78,763 209,503 249,682 311,868 393,185 Profitability/Solvency Ratios (%) EBITDA margin adjusted 6.5 15.2 18.5 22.0 24.3 ROE adjusted 20.3 20.8 18.0 22.4 23.2 ROIC adjusted 8.3 8.1 9.0 12.6 15.5 Net debt to equity 184.4 142.8 166.7 138.6 99.0						
Profitability/Solvency Ratios (%) EBITDA margin adjusted 6.5 15.2 18.5 22.0 24.3 ROE adjusted 20.3 20.8 18.0 22.4 23.2 ROIC adjusted 8.3 8.1 9.0 12.6 15.5 Net debt to equity 184.4 142.8 166.7 138.6 99.0						
EBITDA margin adjusted 6.5 15.2 18.5 22.0 24.3 ROE adjusted 20.3 20.8 18.0 22.4 23.2 ROIC adjusted 8.3 8.1 9.0 12.6 15.5 Net debt to equity 184.4 142.8 166.7 138.6 99.0			1	-,	,	
ROE adjusted 20.3 20.8 18.0 22.4 23.2 ROIC adjusted 8.3 8.1 9.0 12.6 15.5 Net debt to equity 184.4 142.8 166.7 138.6 99.0	• •	-	15.0	18.5	22 N	2/1.3
ROIC adjusted 8.3 8.1 9.0 12.6 15.5 Net debt to equity 184.4 142.8 166.7 138.6 99.0						
Net debt to equity 184.4 142.8 166.7 138.6 99.0	-					
·	_					
10.0 00.0 01.0 00.7 01.0 00.0						
	τοιαι αθοί το σαμιίαι	00.3	01.0	00.4	01.0	50.0

2010

2011

2012E

2013E

2014E

For further data queries on Citi's full coverage universe please contact CIRA Data Services Asia Pacific at CIRADataServicesAsiaPacific@citi.com or +852-2501-2791



Maintain Hold (2M) - Target Price cut to Rs644

Revising down target price to Rs644 (from Rs653 earlier) to factor in (1) 6-20% EPS cut over FY12E-15E (2) roll forward of all multiples and DCF values by 3 months (3) Adani Power at our new target price of Rs105 and (3) removing the 5% conglomerate discount

Figure 1. AEL – Sum Of The Parts

Name of Asset	Valuation Approach	CoE/Multiple	ADE Stake	Equity Value	ADE Value	Per Share
Mundra Ports	At CIRA TP = Rs185	13%-14%	77.5%	370,628	287,200	261
Adani Power	At CIRA TP = Rs105	13%	63.99%	251,290	160,796	146
Machhakatta	DCF as of Dec 2011	13%	100.0%	49,769	49,769	45
Parsa-Kente - PKCL	DCF as of Dec 2011	13%	74.0%	2,453	1,815	2
Parsa-Kente - AMPL	DCF as of Dec 2011	13%	100.0%	11,266	11,266	10
Parsa	DCF as of Dec 2011	13%	100.0%	2,760	2,760	2.5
Chendipada	DCF as of Dec 2011	13%	100.0%	25,130	25,130	23
Bunyu	DCF as of Dec 2011	13%	100.0%	8,413	8,413	8
Galilee Coal Tenement	Book Value		100.0%	20,475	20,475	19
Coal Mining				120,267	119,629	109
BKC	DCF as of Dec 2011	13%	95.0%	19,205	18,245	17
SEMPL	DCF as of Dec 2011	13%	71.3%	14,415	10,271	9
Khatau-Byculla	DCF as of Dec 2011	13%	57.0%	4,007	2,284	2
Khatau-Borivalli	DCF as of Dec 2011	13%	57.0%	4,160	2,371	2
Land Bank			100.0%	1,850	1,850	2
Real Estate	Discount of 30% to NAV			43,638	24,515	22
Trading	Dec12E EV/EBITDA multiple	6x	100.0%	122,715	122,715	112
Agro Business				16,395	10,206	9
City Gas Distribution	DCF as of Dec 2011	13%	100.0%	6,794	6,794	6
Shipping	DCF as of Dec 2011	13%	100.0%	3,417	3,417	3
Bunkering	DCF as of Dec 2011	13%	50.0%	1,159	579	1
Parent Net Cash/ (Debt)					(27,871)	(25)
Target Price					707,979	644

Source: Citi Investment Research and Analysis estimates

Earnings revised downwards

■ We revise down our EPS estimates by 6-20% over FY12E-15E to factor in (1) our recent 3-40% EPS cut in Adani Power and (2) Lower coal trading EBITDA/ton of US\$8.5/ton in FY12E and US\$8.8/ton over FY13E-15E

Figure 2. ADE - EPS Revision

Year End Mar31 (Rsmn)	FY12E	FY13E	FY14E	FY15E
Sales				
Old	380,877	524,253	642,288	745,296
New	379,545	529,449	637,523	741,514
Change	-0.3%	1.0%	-0.7%	-0.5%
EBITDA				
Old	83,795	126,184	161,149	185,724
New	70,142	116,509	154,794	180,160
Change	-16.3%	-7.7%	-3.9%	-3.0%
EBITDA Margin %				
Old	22.0%	24.1%	25.1%	24.9%
New	18.5%	22.0%	24.3%	24.3%
Change	-352	-206	-81	-62
PAT				
Old	42,677	58,206	71,842	85,001
New	34,253	51,768	66,806	80,060
Change	-19.7%	-11.1%	-7.0%	-5.8%
FD EPS (Rs)				
Old	38.8	52.9	65.3	77.3
New	31.1	47.1	60.7	72.8
Change	-19.7%	-11.1%	-7.0%	-5.8%

Source: Citi Investment Research and Analysis estimates

Figure 3. ADE PAT and EPS - CIRA v/s Consensus

-	FY12E	FY13E	FY14E	FY15E
PAT				
CIRA	34,253	51,768	66,806	80,060
Consensus	38,037	51,878	72,895	90,800
Difference	-10%	0%	-8%	-12%
FD EPS				
CIRA	31.14	47.07	60.74	72.79
Consensus	34.58	47.16	65.80	82.50
Difference	-10%	0%	-8%	-12%

Source: Company and Citi Investment Research and Analysis estimates

Disappointing quarter - PAT 28% below expectations

- ADE's 1QFY12 Recurring PAT at Rs5.7bn was flat YoY and 28% below CIRA expectations of Rs7.9bn. The variance of Rs2.4bn at the EBITDA level can be explained by (1) ~ Rs1.4bn of lower trading EBITDA (2) Rs600mn of higher net interest (interest + other income) (3) lower than expected EBITDA from agro, real estate and others.
- Coal trading volumes were up 23% YoY at 10.18mn (CIRA at 11mn tons) and realizations were US\$114/ton assuming USDINR at 45 (v/s CIRA at US\$100/ton). However EBITDA/ton was disappointing at US\$7.8/ton (v/s CIRA at US\$10/ton inline with management guidance). ADE took ~Rs460mn provision in its coal trading business on receivables outstanding for > 365 days. If we add back the same the EBITDA/ton at US\$8.8/ton is still disappointing.

Figure 4. ADE - 1QFY12 Results Review 1QFY11 1QFY12 1QFY12E Year End Mar31 (Rsmn) YoY 34,761 52,046 50% 49,500 - Trading 8,505 141% 8,187 - Power 3,531 - Port 3,611 4,861 35% 5,161 - Agro 13,604 21,554 58% 13,604 - Real Estate 14 249% 0 3,500 - Other 3,484 8,982 158% **Net Sales** 58,971 95,961 79,951 63% **EBITDA** 8,610 11,678 36% 13,345 **EBITDA margin %** 14.6% 12.2% 16.7% Depreciation (1,124)(2,226)(2,127)**EBIT** 7,486 9,452 26% 11,218 **EBIT margin %** 12.7% 9.9% 14.0% 2,996 3,479 16% 4,703 - Trading Margin% 8.6% 6.7% 9.5% 3,203 73% - Power 1,851 3,700 Margin% 52.4% 37.7% 45.2% 2,523 - Port 3,154 25% 3,041 69.9% 64.9% 58.9% Margin% - Agro (25)(33)200 Margin% -0.2% -0.2% 1.5% - Real Estate (3) (61) - Other 351 (232)100 - Unallocable 953 483 -49% 1,000 **Total EBIT** 8,645 9,992 16% 12,744 (2,230)Interest (1,504)48% (2,200)-53% Other income 1,137 539 1,100 Other operating income 22 -96% 22 1 PBT 7,141 7,763 9% 10,141 (736)(942)(1,217)Tax Tax Rate 10.3% 12.0% 12.1% (798)Minorities (1,123)(982)Associates 48 **Recurring PAT** 5,655 5,698 1% 7,942 Exceptionals (8) (0) Reported PAT 5,647 5,698 1% 7,942 Source: Citi Investment Research and Analysis

Year End Mar31	1QFY11	1QFY12	YoY
Coal Trading			
Qty (mn tonnes)	8.27	10.18	23%
Sales	34,230	52,046	52%
Sales/tom	4,139	5,113	
EBITDA	3,450	3,560	3%
Margin	10.1%	6.8%	
EBITDA/Ton	417	350	-16%
Power Generation			
Kwh (mn)	1,030	2,898	181%
Sales	3,531	8,505	141%
ASP	3.43	2.93	
EBITDA	2,200	4,580	108%
Rs/kWh	2.14	1.58	
Ports			
Cargo (mn tons)	12.62	15.08	19%
Sales	3,611	4,861	35%

3,110

86.1%

1.000

9,760

3,890

80.0%

190

12,220

25%

5%

25%

Source: Company and Citi Investment Research and Analysis

EBITDA

EBITDA/Ton

Total EBITDA

Margin

Others EBITDA

Figure 5. ADE - 1QFY12 Operational Results Review

Adani Power disappoints too with PAT 26% below expectations

- 1QFY12 PAT at 1.8bn was 26% below CIRA expectations. We are not disappointed that: (1) due to maintenance shut downs PLFs were lower; (2) merchant tariffs were down 44% YoY; and (3) fuel costs were high at Rs1.04/kWh of generation (CIRA Rs0.95/kWh).
- Our disappointment stems from the fact that just like 4Q11 when merchant sales percentage was low at 11.7%, in 1Q12 it was once again low at 9.3%. This is the second time the company has disappointed on quantum of merchant sales. Despite management's expectations of selling a big portion of the output from 4 units of 330MW in merchant markets, most of it got sold to GUVNL at PPA rates before the start of the PPA.
- Lower merchant sales in 1Q12 suggest a big quantum from unit # 1 660MW was sold at PPA rates even before start of PPA. This raises questions on business model of making supernormal RoEs by selling power at merchant rates (Rs3.50-4.50/kWh) v/s PPA rates (Rs2.35-2.90/kWh) pre PPA.
- Our merchant quantum assumption in FY12E is not conservative as we assume 5.1bn units of merchant sales in FY12E. According to management, 480MW PPA with UP at net ASP of Rs4/kWh starts from Jul11 implying in next 9 months this will lead to 3.2bn units of merchant sales. To this If we add 1Q12 merchant sales of 270mn units and 3 months of the highest merchant sales done from 4X330MW = 320X3 = 960mn units one arrives at 4.4bn units of merchant sales v/s our assumption of 5.1bn units

Figure 6. Adani Power - 1QFY12 Results Review

Rsmn	1QFY11	4QFY11	1QFY12	YoY	1QFY12E
Generation (mu)	1,153	3,007	3,190	177%	3,190
Sales (mu)	1,030	2,729	2,898	181%	2,898
Auxiliary Consumption	10.7%	9.3%	9.2%		9.2%
GUVNL Sales (mn kWh)	850	2,409	2,628	209%	2,463
Merchant sales (mn kWh)	180	320	270	50%	435
merchant % of total	17.5%	11.7%	9.3%		15.0%
Custom Duty	0	271	290		290
- GUVNL	0	239	263		246
- Merchant	0	32	27		43
Rate (Rs/kwh)	0.10	0.10	0.10		0.10
Net Sales	3,531	8,367	8,187		8,831
Net ASPs	3.43	3.07	2.82	-18%	3.05
- GUVNL Sales	2,370	6,936	7,215		6,925
GUVNL Tariff	2.79	2.88	2.75	-2%	2.81
- Merchant Sales	1,161	1,431	972		1,906
Merchant Tariff	6.45	4.47	3.60	-44%	4.39

Source: Company and Citi Investment Research and Analysis estimates

Figure 7. Adani Power – 1QFY12 Results Review

Rsmn	1QFY11	4QFY11	1QFY12	YoY	1QFY12E
Net Sales	3,531	8,367	8,187	132%	8,831
Rs/kWh per unit sold	3.43	3.07	2.82	-18%	3.05
Consumption of RM	(1,098)	(2,580)	(3,333)		(3,031)
Rs/kWh per unit generated	0.95	0.86	1.04		0.95
O&M Cost	(301)	(851)	(752)		(904)
Rs/kWh per unit sold	0.29	0.31	0.26		0.31
EBITDA	2,132	4,937	4,102	92%	4,897
EBITDA margin	60.4%	59.0%	50.1%	0270	55.4%
Rs/kWh per unit sold	2.07	1.81	1.42		1.69
Depreciation	(279)	(711)	(1,040)		(782)
Rs/kWh per unit sold	0.27	0.26	0.36		0.27
EBIT	1,852	4,225	3,062	65%	4,114
EBIT margin	52%	50%	37%		47%
Interest	(433)	(962)	(886)		(1,200)
Other income	79	60	81		70
PBT	1,499	3,323	2,256	51%	2,984
Tax	(354)	(1,768)	(488)		(597)
Rate%	23.6%	53.2%	21.6%		20.0%
PAT	1,145	1,555	1,769	54%	2,387
PAT margin	32.4%	18.6%	21.6%	J . 70	27.0%
2Q and 3Q GUVNL Duties	0	188	0		0
Reported PAT	1,145	1,743	1,769	54%	2,387

Source: Company and Citi Investment Research and Analysis estimates

MPSEZ PAT 12% below CIRA expectations

- PAT at Rs2.54bn +20% YoY was 12% below CIRA at Rs2.89bn. Sales at Rs5.1bn +27% YoY was 5% below CIRA at Rs5.4bn. EBITDA Margins at 67.8% declined 124bps YoY, but was better than expected.
- There was disappointment on liquid cargo volumes (expected to spill over to subsequent quarters). Dry bulk and containers (+24%) continue to be robust. We had assumed some crude volumes for the GSSRL Bhatinda refinery to come through in 1QFY12. The shortfall in liquid volumes probably means that this spills over to the subsequent quarters. Coal volume growth has been better than expected.
- Our FY12E cargo assumes 15% growth in steady state cargo and ~ 23% growth in containers. We also have volume kicker for coal (Adani Power and Tata Power) and liquid (GGSRL) which are more back-ended towards 2HFY12.

Figure 8. MPSEZ 1QFY12 Results Review

Year End Dec31 (Rsmn)	1Q11	1Q12	YoY	1Q12E
Net Sales	4059	5161	27%	5411
EBITDA	2798	3493	25%	3517
EBITDA Margin	68.9%	67.7%		65.0%
Depreciation	(476)	(587)		(586)
EBIT	2321	2906	25%	2931
EBIT Margin	57.2%	56.3%		54.2%
Interest net	(247)	(331)		
Other Income	8	` 4		10
Other Operating Income	98	135		100
РВТ	2180	2714	25%	3041
Total Tax	(67)	(171)		(152)
Tax Rate	3.1%	6.3%		5.0%
PAT	2113	2544	20%	2889

Source: Company and Citi Investment Research and Analysis estimates

Adani Enterprises

Company description

Adani Enterprises (ADE), founded in 1988 as a partnership firm, has interests in trading, coal mining, real estate development, shipping, bunkering, city gas distribution, power generation, edible oil refining, grain storage and food processing. The company went public in 1994. In the initial years of operation, it focused on trading activities including trading of agro products, mineral oils, metal scrap, precious metals, textile products and fertilizers. With the onset of the infrastructure development cycle in the earlier part of this decade, ADE moved away from being a pure trader to being an infrastructure asset developer to reduce the risk from fluctuating trading volumes. Today, the company has interests in coal mine development, power generation, city gas distribution, real estate development, and food storage and processing. Apart from moving into infrastructure asset development, the company has diversified into the trading of coal (coal imports into India) and power trading. Recently Mundra Ports and SEZ has also been amalgamated into ADE.

Investment strategy

We rate ADE Hold/Medium Risk for the following reasons: ADE has taken some very ambitious steps in the recent past: 1) purchase of a 100% interest in the Galilee coal tenement for US\$455mn; 2) coal purchase agreement with Regional Government of Sumatra Selatan and PT Bukit Asam; and 3) MPSEZ wining the AU\$1.8bn bid for Abbott Point. At the heart of this strategy is forward/ backward integration and exploiting the synergies in its ports, power, contract coal mining, coal ownership coal and coal trading businesses. We are in consonance with the company's strategy but we do worry if the company is chewing a little more and a little too fast, than it can digest. We believe the easy money is off the table.

Valuation

Our Rs644 target price for Adani Enterprises is derived using a sum of the parts (SOTP) methodology given the conglomerate nature of the business. By far the biggest constituents of our fair value at 39% and 22% are the group's ports and power divisions respectively, which we value using a DCF model in which FCFE is discounted at a cost of equity of 12-14%. The next biggest contributors to the "value pie" at respective weightings of 16% and 17% are Coal Mining (valued using a DCF and CoE discount rate of 13%) and Trading (Dec12E EV/EBITDA of 6x). Real Estate (3%), Agri (1%) and City Gas also contribute to an overall fair value of Rs644/share (excluding net debt).

Risks

Our quantitative risk-rating system, which tracks 260-day historical share price volatility, assigns a Low Risk rating to Adani Enterprises. We assign a Medium risk rating to factor in the impact of the recent reported Lokayukta report. Key downside risks to our target price lie in: (1) poor project execution; (2) commodity trading; (3) financial closure; (4) environmental and legal clearance; (5) coal license in Bunyu; (6) real estate volumes; (7) resource estimation risk; and (8) inadequate coal in Bunyu to fire the Mundra project. Key upside risks to our target price lie in: (1) better-than-expected project execution; (2) more project wins in coal mining, ports and power; and (3) higher cash generation in trading businesses.

Appendix A-1

Analyst Certification

The research analyst(s) primarily responsible for the preparation and content of this research report are named in bold text in the author block at the front of the product except for those sections where an analyst's name appears in bold alongside content which is attributable to that analyst. Each of these analyst(s) certify, with respect to the section(s) of the report for which they are responsible, that the views expressed therein accurately reflect their personal views about each issuer and security referenced and were prepared in an independent manner, including with respect to Citigroup Global Markets Inc and its affiliates. No part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) expressed by that research analyst in this report.

IMPORTANT DISCLOSURES



Citigroup Global Markets Inc. or its affiliates has received compensation for investment banking services provided within the past 12 months from Adani Enterprises.

Citigroup Global Markets Inc. or an affiliate received compensation for products and services other than investment banking services from Adani Enterprises in the past 12 months.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following as investment banking client(s): Adani Enterprises.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following as clients, and the services provided were non-investment-banking, securities-related: Adani Enterprises.

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability which includes investment banking revenues

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citi Investment Research & Analysis product ("the Product"), please contact Citi Investment Research & Analysis, 388 Greenwich Street, 28th Floor, New York, NY, 10013, Attention: Legal/Compliance. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at www.citigroupgeo.com. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

Citi Investment Research & Analysis Ratings Distribution

	12 WORUT Kaung		ıy	Relative Ratilig		
Data current as of 30 Jun 2011	Buy	Hold	Sell	Buy	Hold	Sell
Citi Investment Research & Analysis Global Fundamental Coverage	54%	36%	11%	10%	81%	10%
% of companies in each rating category that are investment banking clients	45%	41%	42%	50%	42%	44%

Guide to Citi Investment Research & Analysis (CIRA) Fundamental Research Investment Ratings:

CIRA's stock recommendations include a risk rating and an investment rating.

Risk ratings, which take into account both price volatility and fundamental criteria, are: Low (L), Medium (M), High (H), and Speculative (S).

Investment ratings are a function of CIRA's expectation of total return (forecast price appreciation and dividend yield within the next 12 months) and risk rating.

Analysts may place covered stocks "Under Review" in response to exceptional circumstances (e.g. lack of information critical to the analyst's thesis) affecting the company and/or trading in the company's securities (e.g. trading suspension). Stocks placed "Under Review" will be monitored daily by management. As soon as practically possible, the analyst will publish a note re-establishing a rating and investment thesis.

To satisfy regulatory requirements, we correspond Under Review to Hold in our ratings distribution table for our 12-month fundamental rating system. However, we reiterate that we do not consider Under Review to be a recommendation.

Relative three-month ratings: CIRA may also assign a three-month relative call (or rating) to a stock to highlight expected out-performance (most preferred) or under-performance (least preferred) versus the analyst's coverage universe over a 3 month period. The relative call may highlight a specific near-term catalyst or event impacting the company or the market that is anticipated to have a short-term price impact on the equity securities of the company. Absent any specific catalyst the analyst(s) will indicate the most and least preferred stocks in his coverage universe, explaining the basis for this short-term view. This three-month view may be different from and does not affect a stock's fundamental equity rating, which reflects a longer-term total absolute return expectation. For purposes of NASD/NYSE ratings-distribution-disclosure rules, most preferred calls correspond to a buy recommendation and least preferred calls correspond to a sell recommendation. Any stock not assigned to a most preferred or least preferred call is considered non-relative-rated (NRR). For purposes of NASD/NYSE ratings-distribution-disclosure rules we correspond NRR to Hold in our ratings distribution table for our 3-month relative rating system. However, we reiterate that we do not consider NRR to be a recommendation.

For securities in emerging markets (Asia Pacific, Emerging Europe/Middle East/Africa, and Latin America), investment ratings are:Buy (1) (expected total return of 15% or more for Low-Risk stocks, 20% or more for Medium-Risk stocks, 30% or more for High-Risk stocks, and 40% or more for Speculative stocks); Hold (2) (5%-15% for Low-Risk stocks, 10%-20% for Medium-Risk stocks, 15%-30% for High-Risk stocks, and 20%-40% for Speculative stocks); and Sell (3) (5% or less for Low-Risk stocks, 10% or less for Medium-Risk stocks, 15% or less for High-Risk stocks, and 20% or less for Speculative stocks).

Investment ratings are determined by the ranges described above at the time of initiation of coverage, a change in investment and/or risk rating, or a change in target price (subject to limited management discretion). At other times, the expected total returns may fall outside of these ranges because of market price movements and/or other short-term volatility or trading patterns. Such interim deviations from specified ranges will be permitted but will become subject to review by Research Management. Your decision to buy or sell a security should be based upon your personal investment objectives and should be made only after evaluating the stock's expected performance and risk.

NON-US RESEARCH ANALYST DISCLOSURES

Non-US research analysts who have prepared this report (i.e., all research analysts listed below other than those identified as employed by Citigroup Global Markets Inc.) are not registered/qualified as research analysts with FINRA. Such research analysts may not be associated persons of the member organization and therefore may not be subject to the NYSE Rule 472 and NASD Rule 2711 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account. The legal entities employing the authors of this report are listed below:

Citigroup Global Markets India Private Limited

Venkatesh Balasubramaniam; Deepal Delivala; Atul Tiwari, CFA; Rishi V Iyer

OTHER DISCLOSURES

The subject company's share price set out on the front page of this Product is quoted as at 10 August 2011 01:09 PM on the issuer's primary market.

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the issuer(s) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal hasis

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citi Investment Research & Analysis (CIRA) does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of CIRA to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is n

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc.

takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

Important Disclosures for Morgan Stanley Smith Barney LLC Customers: Morgan Stanley & Co. Incorporated (Morgan Stanley) research reports may be available about the companies that are the subject of this Citi Investment Research & Analysis (CIRA) research report. Ask your Financial Advisor or use smithbarney.com to view any available Morgan Stanley research reports in addition to CIRA research reports.

Important disclosure regarding the relationship between the companies that are the subject of this CIRA research report and Morgan Stanley Smith Barney LLC and its affiliates are available at the Morgan Stanley Smith Barney disclosure website at www.morganstanleysmithbarney.com/researchdisclosures. The required disclosures provided by Morgan Stanley and Citigroup Global Markets, Inc. on Morgan Stanley and CIRA research relate in part to the separate businesses of Citigroup Global Markets, Inc. and Morgan Stanley that now form Morgan Stanley Smith Barney LLC, rather than to Morgan Stanley Smith Barney LLC in its entirety. For Morgan Stanley and Citigroup Global Markets, Inc. specific disclosures, you may refer to www.morganstanley.com/researchdisclosures and https://www.citigroupgeo.com/geopublic/Disclosures/index_a.html.

This CIRA research report has been reviewed and approved on behalf of Morgan Stanley Smith Barney LLC. This review and approval was conducted by the same person who reviewed this research report on behalf of CIRA. This could create a conflict of interest.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by. The Product is made available in Australia through Citigroup Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992), participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. The Product is made available in Brazil by Citigroup Global Markets Brasil - CCTVM SA, which is regulated by CVM - Comissão de Valores Mobiliários, BACEN - Brazilian Central Bank, APIMEC -Associação dos Analistas e Profissionais de Investimento do Mercado de Capitais and ANBID - Associação Nacional dos Bancos de Investimento. Av. Paulista, 1111 - 11° andar - CEP. 01311920 - São Paulo - SP. If the Product is being made available in certain provinces of Canada by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. This product is available in Chile through Banchile Corredores de Bolsa S.A., an indirect subsidiary of Citigroup Inc., which is regulated by the Superintendencia de Valores y Seguros. Agustinas 975, piso 2, Santiago, Chile. The Product is made available in France by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 1-5 Rue Paul Cézanne, 8ème, Paris, France. The Product is distributed in Germany by Citigroup Global Markets Deutschland AG ("CGMD"), which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). CGMD, Reuterweg 16, 60323 Frankfurt am Main. If the Product is made available in Hong Kong by, or on behalf of, Citigroup Global Markets Asia Ltd., it is attributable to Citigroup Global Markets Asia Ltd., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Product is made available in Hong Kong by The Citigroup Private Bank to its clients, it is attributable to Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. The Citigroup Private Bank and Citibank N.A. is regulated by the Hong Kong Monetary Authority. The Product is made available in India by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. The Product is made available in Indonesia through PT Citigroup Securities Indonesia. 5/F, Citibank Tower, Bapindo Plaza, Jl. Jend. Sudirman Kav. 54-55, Jakarta 12190. Neither this Product nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable capital market laws and regulations. This Product is not an offer of securities in Indonesia. The securities referred to in this Product have not been registered with the Capital Market and Financial Institutions Supervisory Agency (BAPEPAM-LK) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market laws and regulations. The Product is made available in Israel through Citibank NA, regulated by the Bank of Israel and the Israeli Securities Authority. Citibank, N.A, Platinum Building, 21 Ha'arba'ah St, Tel Aviv, Israel. The Product is made available in Italy by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. Foro Buonaparte 16, Milan, 20121, Italy. The Product is made available in Japan by Citigroup Global Markets Japan Inc. ("CGMJ"), which is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Shin-Marunouchi Building, 1-5-1 Marunouchi, Chiyoda-ku, Tokyo 100-6520 Japan. If the Product was distributed by SMBC Nikko Securities Inc. it is being so distributed under license. In the event that an error is found in an CGMJ research report, a revised version will be posted on the Firm's Global Equities Online (GEO) website. If you have questions regarding GEO, please call (81 3) 6270-3019 for help. The Product is made available in Korea by Citigroup Global Markets Korea Securities Ltd., which is regulated by the Financial Services Commission, the Financial Supervisory Service and the Korea Financial Investment Association (KOFIA). Citibank Building, 39 Da-dong, Jung-qu, Seoul 110-180, Korea. KOFIA makes available registration information of research analysts on its website. Please visit the following website if you wish to find KOFIA registration information on research analysts of Citigroup Global Markets Korea Securities Ltd. http://dis.kofia.or.kr/fs/dis2/fundMgr/DISFundMgrAnalystPop.jsp?companyCd2=A03030&pageDiv=02. The Product is made available in Malaysia by Citigroup Global Markets Malaysia Sdn Bhd, which is regulated by Malaysia Securities Commission. Menara Citibank, 165 Jalan Ampang, Kuala Lumpur, 50450. The Product is made available in Mexico by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, Integrante del Grupo Financiero Banamex ("Accival") which is a wholly owned subsidiary of Citigroup Inc. and is regulated by Comision Nacional Bancaria y de Valores. Reforma 398, Col. Juarez, 06600 Mexico, D.F. In New Zealand the Product is made available through Citigroup Global Markets New Zealand Ltd. (Company Number 604457), a Participant of the New Zealand Exchange Limited and regulated by the New Zealand Securities Commission. Level 19, Mobile on the Park, 157 Lambton Quay, Wellington. The Product is made available in Pakistan by Citibank N.A. Pakistan branch, which is regulated by the State Bank of Pakistan and Securities Exchange Commission, Pakistan. AWT Plaza, 1.1. Chundrigar Road, P.O. Box 4889, Karachi-74200. The Product is made available in the Philippines through Citicorp Financial Services and Insurance Brokerage Philippines, Inc., which is regulated by the Philippines Securities and Exchange Commission. 20th Floor Citibank Square Bldg. The Product is made available in Poland by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Nadzoru Finansowego. Dom Maklerski Banku Handlowego S.A. ul. Senatorska 16, 00-923 Warszawa. The Product is made available in the Russian Federation through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license

issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in Singapore through Citigroup Global Markets Singapore Pte. Ltd., a Capital Markets Services Licence holder, and regulated by Monetary Authority of Singapore. 1 Temasek Avenue, #39-02 Millenia Tower, Singapore 039192. The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. This report is distributed in Singapore by Citibank Singapore Ltd ("CSL") to selected Citigold/Citigold Private Clients. CSL provides no independent research or analysis of the substance or in preparation of this report. Please contact your Citigold//Citigold Private Client Relationship Manager in CSL if you have any gueries on or any matters arising from or in connection with this report. Citigroup Global Markets (Pty) Ltd. is incorporated in the Republic of South Africa (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in Spain by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 29 Jose Ortega Y Gassef, 4th Floor, Madrid, 28006, Spain. The Product is made available in Taiwan through Citigroup Global Markets Taiwan Securities Company Ltd., which is regulated by Securities & Futures Bureau. No portion of the report may be reproduced or quoted in Taiwan by the press or any other person. 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan. If the Product is related to non-Taiwan listed securities, neither the Product nor any information contained in the Product shall be considered as advertising the securities or making recommendation of the securities. The Product is made available in Thailand through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Thailand. The Product is made available in Turkey through Citibank AS which is regulated by Capital Markets Board. Tekfen Tower, Eski Buyukdere Caddesi # 209 Kat 2B, 23294 Levent, Istanbul, Turkey. In the U.A.E, these materials (the "Materials") are communicated by Citigroup Global Markets Limited, DIFC branch ("CGML"), an entity registered in the Dubai International Financial Center ("DIFC") and licensed and regulated by the Dubai Financial Services Authority ("DFSA") to Professional Clients and Market Counterparties only and should not be relied upon or distributed to Retail Clients. A distribution of the different CIRA ratings distribution, in percentage terms for Investments in each sector covered is made available on request. Financial products and/or services to which the Materials relate will only be made available to Professional Clients and Market Counterparties. The Product is made available in United Kingdom by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in United States by Citigroup Global Markets Inc, which is a member of FINRA and registered with the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority.

Pursuant to Comissão de Valores Mobiliários Rule 483, Citi is required to disclose whether a Citi related company or business has a commercial relationship with the subject company. Considering that Citi operates multiple businesses in more than 100 countries around the world, it is likely that Citi has a commercial relationship with the subject company.

Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to CIRA's Products can be found at www.citigroupgeo.com.

Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations.

The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would not be permitted.

Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. The Product does not purport to identify the nature of the specific market or other risks associated with a particular transaction. Advice in the Product is general and should not be construed as personal advice given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs. Prior to acquiring any financial product, it is the client's responsibility to obtain the relevant offer document for the product and consider it before making a decision as to whether to purchase the product. CIRA concurrently disseminates its research via proprietary and non-proprietary electronic distribution platforms. Periodically, individual analysts may also opt to circulate research to one or more clients by email. Such email distribution is discretionary and is done only after the research has been disseminated via the aforementioned distribution channels.

© 2011 Citigroup Global Markets Inc. Citi Investment Research & Analysis is a division of Citigroup Global Markets Inc. Citi and Citi with Arc Design are trademarks and service marks of Citigroup Inc. and its affiliates and are used and registered throughout the world. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure of this report (the "Product"), including, but not limited to, redistribution of the Product by electronic mail, posting of the Product on a website or page, and/or providing to a third party a link to the Product, is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient to any third party. Where included in this report, MSCI sourced information is the exclusive property of Morgan Stanley Capital International Inc. (MSCI). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, redisseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI, Morgan Stanley Capital International and the MSCI indexes are services marks of MSCI and its affiliates. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the

Adani Enterprises (ADEL.BO)

10 August 2011

Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST